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Use of Folic Acid, Vitamin B6, and Vitamin B12 to
Lower Homocysteine Concentrations
By: Julie Long, PharmD Candidate
Homocysteine is an amino acid
derived from the dietary amino
acid methionine. Elevations in
homocysteine have been associated with endothelial dysfunction, vascular smooth muscle
growth, arterial stiffening, procoagulant activity, reduction in
arterial vasodilation, proinflammatory responses, and oxidative
stress. In 1969, it was proposed
that homocysteine caused
atherosclerosis. The Homocysteine Studies Collaboration suggested a 25% reduction in homocysteine is associated with an
11% lower risk of ischemic heart
disease and 19% lower risk of
stroke.
Patients with hyperhomocysteinemia have an inherent inability to metabolize homocysteine,
which causes an increase in serum homocysteine concentrations. This increase in homocysteine may result in mental retardation, ectopic lenses, skeletal
abnormalities, premature atherosclerosis, and premature thrombosis. Three enzymes and three
cofactors are involved in the
breakdown of homocysteine,
cystathione β-synthase using vitamin B6, methionine synthase

using vitamin B12, and methylene
tetrahydrofolate reductase using
folic acid. By providing exogenous cofactor, the amount of homocysteine can be reduced by increasing its metabolism.
Foltx® is a medical food containing folic acid (2.5 mg), vitamin B6
(25 mg), and vitamin B12 (2 mg)
that is approved for the dietary
management of hyperhomocysteinemia. It has been hypothesized that lowering homocysteine
concentrations may be extrapolated to patients with normal to
mild elevations in homocysteine
to reduce the risk of cardiovascular (CV) disease. Several clinical
trials have been conducted to test
this hypothesis.
The Norwegian Vitamin Trial
(NORVIT) was a randomized,
double-blind, placebo-controlled
trial that evaluated the potential
benefit of B vitamins in 3749 men
and women after a myocardial infarction (MI). Participants were
randomized to one of four groups:
(1) 0.8 mg folic acid, 0.4 mg vitamin B12, and 40 mg vitamin B6;
(2) 0.8 mg folic acid and 0.4 mg
vitamin B12; (3) 40 mg vitamin B6;
or (4) placebo. The primary end-
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point was a composite of nonfatal
and fatal MI or, and sudden cardiac death. Patients were followed up to 2.5 to 3 years.
In groups that received folic acid,
homocysteine concentrations were
reduced by approximately 26%;
however, this did not affect the
primary endpoint. At the end of
3 years, treatment with folic acid,
with or without B vitamins, did
not significantly reduce event
rates. The combination of folic
acid, vitamin B12, and vitamin B6
actually increased the risk of an
event, with a hazard ratio of 1.2
(95% CI 1.02 to 1.41, p=0.03).
Treatment with vitamin B6 was
associated with a 17% increase in
the risk of myocardial infarction
(p=0.05), and the combination of
all 3 vitamins was associated with
a 30% increase in the risk of nonfatal myocardial infarction
(p=0.05). However, these data
were not adjusted for multiple
comparisons. The NORVIT authors concluded that treatment
with folic acid with or without B
vitamins is not recommended because it did not lower the risk of
recurrent CV disease in patients
following an MI.
The Heart Outcomes Prevention
Evaluation (HOPE-2) trial was a
randomized, double-blind, placebo-controlled trial that evaluated the potential benefit of B vitamins in 5522 patients at high
risk of major vascular events. Patients were included if they had a
history of coronary, cerebrovascular or peripheral vascular disease,
or diabetes and an additional risk
factor for atherosclerosis were
randomized to receive the combination of folic acid (2.5 mg), vita-
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min B12 (1 mg), and vitamin B6
(50 mg), or placebo. Serum homocysteine concentrations were
measured at baseline, 2 years,
and 5 years. The treatment arm
achieved a 25% reduction in homocysteine concentrations.
However, the primary endpoint
(ie, composite of death from cardiovascular causes, MI, or
stroke) did not reach statistical
significance. However, the secondary endpoint (ie, incidence of
stroke) did achieve a 25% decrease in relative risk (p=0.03).
Hospitalization for unstable angina was associated with a 24%
increase in relative risk (p=0.02).
The results were not adjusted for
multiple comparisons, and were
difficult to explain biologically.
Therefore, the authors do not
recommend treatment with folic
acid and B vitamins to lower the
incidence of composite CV
death.
The Vitamin Intervention for
Stroke Prevention (VISP) study
was a randomized, double-blind
trial to evaluate the potential
benefit of B vitamins in 3680
patients after a nondisabling
cerebral infarction. Patients were
randomized to high dose (2.5 mg
folic acid, 0.4 mg vitamin B6,
25 mg vitamin B12) or low dose
(20 mcg folic acid, 0.2 mg vitamin B6, 6 mcg vitamin B12) vitamin combination. After 2 years,
there was no statistically significant difference between the
treatment groups in the risk of
stroke, coronary heart disease
event, or death.
The Atherosclerosis and Folic
Acid Supplementation Trial
(ASFAST) was a randomized,

double-blind, placebo-controlled
clinical trial that evaluated 315
patients with chronic renal failure.
Participants were randomized to
treatment with 15 mg folic acid or
placebo and followed for an average of 3.5 years. Despite a 19%
reduction in homocysteine concentration in the folic acid group,
there were no statistically significant differences in cardiovascular
event rates, leading the authors to
conclude that treatment with folic
acid is not recommended to improve cardiovascular morbidity
and mortality in patients with
chronic renal failure.
Four trials that assessed similar,
but varied patient populations all
reached the same conclusion. Homocysteine concentrations were
lowered, but treatment with folic
acid, vitamin B6, and vitamin B12
was not the anticipated solution to
prevent cardiovascular disease.
Several hypotheses have been
suggested by Loscalzo to explain
the treatment failure. Homocysteine may not be a cause of
atherosclerosis. Homocysteine
may be a surrogate marker for another species that cause atherosclerosis or therapy with folic acid
and the B vitamins may produce
adverse effects that offset the homocysteine lowering benefit.
There are 3 potential biochemical
mechanisms by which exogenous
folic acid and B vitamins may be
detrimental. First, folic acid promotes cell proliferation through
the synthesis of thymidine, which
may occur in an atherosclerotic
plaque. Second, when homocysteine metabolism is increased
using the B vitamin cofactors,
s-adenosylmethionine concentra-
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tions are increased, leading to an
increase in methylation reactions
in the cell. Methylation of DNA
appears to play a role in atherosclerosis. Third, as the methylation potential in the cell increases,
l-arginine is converted to dimethylarginine, which inhibits the activity of nitric oxide synthase, increasing the risk of vascular disease.
Treatment with folic acid and B
vitamins does lower homocysteine
concentrations, but does not reduce cardiovascular morbidity and
mortality, and should therefore not
be recommended. The American
Heart Association (AHA) does not
recognize hyperhomocysteinemia
as a major risk factor for CV disease. Additionally, AHA does not
recommend the widespread use of
folic acid and B vitamins to
reduce the risk of heart disease
and stroke.
References are available upon request

Nephrogenic Systemic
Fibrosis/Nephrogenic
Fibrosing Dermopathy
Associated with
Contrast Agents
By: Kathryn Noyes, PharmD
Pharmacy Practice Resident
Nephrogenic Systemic Fibrosis/
Nephrogenic Fibrosing Dermopathy (NSF/NFD) is a newly diagnosed disease state that is potentially associated with the administration of gadolinium-containing
contrast agents.
NFD is a sclerotic cutaneous condition presenting in patients with
end-stage renal disease and is
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characterized with the appearance of sclerotic plaques, histologically resembling scleromyxedema-like features, on the
distal extremities and trunk. The
skin plaques may result in severe
contractions and limited mobility.1,2 NSF is characterized as a
variation of NFD that involves
fibrosis of other organs (eg,
lungs, liver, and heart). NSF/
NFD is a debilitating and potentially fatal disease.
The Centers for Disease Control
identified 49 patients with NFD
between 1997 and 2002.2 In a
small case control study of these
patients, common risk factors
were not uncovered.2 It has been
suggested that because NFD had
not been described prior to 1997
that the sudden occurrence of
this disease may be likely caused
by a new agent or technique of
examination.4 While severe kidney disease predisposes patients
to NFD/NSF only a small
amount of patients develop the
condition, suggesting that there
is another factor involved in the
etiology of this disease.
Since June 2006, the Food and
Drug Administration (FDA) has
been reviewing reports detailing
patients who developed NSF/
NFD after they received a gadolinium-based contrast agent during a magnetic resonance imaging scan (MRI) or magnetic
resonance angiography (MRA).
As of December 21, 2006, 90
individuals with NSF/NFD had
been reported to FDA. All patients had moderate (GFR < 60
mL/min/1.73m2) to end-stage
renal disease (GFR < 15 mL/
min/1.73m2) prior to their MRI

or MRA with a gadolinium-based
contrast agent. The NSF/NFD
began 2 days to 18 months after
undergoing a contrast-enhance
MRI or MRA. Many of these
patients received a dose of gadolinium-based contrast agent exceeding product labeling recommendations. Researchers have detected gadolinium deposits in skin
biopsies from patients with NSF/
NFD.4,5
Currently, the approved gadolinium-containing products include
g a d o d i a mi d e ( O m n i s c a n ® ) ,
gadopentetate dimeglumine
(Magnevist®), gadoteridol
(Prohance®), gadobenate dimeglumine (Multihance®), and gadoversetamide (OptiMARK®). None of
these agents have been approved
by FDA for MRA and the dose of
gadolinium-containing products
used in MRA may be up to 3
times higher than the approved
dose for MRI.6 These agents are
all excreted via the kidney and
have similar pharmacokinetics
profiles.8
The possible connection between
NFD and gadolinium-containing
contrast has been theorized with a
possible mechanism related to the
poor solubility of free gadolinium
ions and their likelihood of forming precipitates with phosphate,
carbonate, or hydroxyl, which are
deposited in the skin, muscle,
bone, liver and other organs.4 The
presence of gadolinium in areas of
calcium phosphate deposition in
the blood vessels of one NFD patient was identified in a case report by Boyd and colleagues.9
Physicians should carefully assess
the need for gadolinium-based
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contrast agents in this patient
population when performing an
MRI or MRA. FDA recommends
that physicians weigh the benefits
and risks of performing an MRI or
MRA with contrast in patients
with moderate to end-stage renal
disease. An alternative imaging
method and/or contrast agents
should be considered. Additionally, dialysis may be considered
in these patients; however, there
are no published data to support
the utility of dialysis to prevent or
treat NSF/NFD.
For more information please visit
the FDA Web page at
www.fda.gov/cder/drug/infopage/
gcca/default.htm.

Med•U•Way to Focus
on Pandemic Influenza
The next MED•U•WAY
Conference will focus on
pandemic influenza and the use of
neuraminidase inhibitors. The
program will be held on Thursday,
January 18, 2006, at 12:00 PM, in
2 West Amphitheater.
The featured speakers will be
Michael Schmidt, PHD,
Department of Microbiology and
Immunology; Deborah Stier
Carson, PharmD, FCCP,
Professor, College of Pharmacy;
Robert Ball, MD, MPH, Infectious
Disease Consultant and
Epidemiologist, SCDHEC.
Attendees will receive 1 credit
hour of continuing education, and
lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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Formulary Update
The Pharmacy and Therapeutics Committee recently approved the actions listed below,
which were effective on December 18, 2006 unless otherwise
stated.
Additions with Restrictions:
Sildenafil (Revatio®)
Prescribing is restricted to patients who have pulmonary arterial hypertension.
20-mg tablet
Gadobenate dimeglumine
(Multihance®)
Prescribing is restricted to adult
patients undergoing contrastenhanced MRI of the CNS, adult
patients undergoing hepatobiliary contrast-enhanced imaging
for metastatic detection or a subset of MRCP (ie, evaluation of
the intrahepatic biliary tree), or
patients who have end-stage renal disease requiring dialysis.
529-mg/mL vials
Addition:
Polyethylene glycol (generic)
17-gram, unit-dose packets
Automatic Therapeutic Substitution (ATS) Change
The ATS for polyethylene glycol
will be updated to reflect the addition of the pre-packaged polyethylene glycol doses. The updated ATS protocol is located on
the on the Formulary and Drug
Information Resources Web
page.
Restriction NOT Changed:
Aprepitant (Emend®)
The request to extend the restriction to the anesthesiology service for post operative nausea

and vomiting (PONV) was not
approved due to the lack of evidence of superiority to other
agents and the substantial cost difference as compared with ondansetron.
Restriction Removed:
**Effective date to be assigned for
March 2007**
Meropenem (Merrem®)
The formulary restriction will be
removed with the deletion of
imipenem/cilastatin. The formulary active date has been extended
to create appropriate use and dosing guidelines for meropenem and
to provide appropriate education.
Deletion
**Effective date to be assigned for
March 2007**
Imipenem/cilastatin (Primaxin®)
Line extensions
Pantoprazole (Protonix®)
20-mg tablet
Levetiracetam (Keppra®)
500-mg/5-mL injection
Leuprolide acetate (Lupron®)
7.5-, 22.5-, and 30-mg injection
Updated Chart
The Formulary Medications Requiring Filtration Prior to Administration at MUSC-MC chart
has been revised to reflect any
changes in the formulary since
September 2005. The changes
include the addition of cetuximab
(Erbitux®) and updated references
for each medication. The chart
was reviewed and approved by the
Medication Cycle Improvement
Group and is available on the Formulary and Drug Information Resources Web page.

